Get our latest issue now

available for iOS, Android & web

latest issue

FDA panel mixed on Dynavax hepatitis vaccine

Daily News | November 16, 2012

Kevin Grogan

FDA panel mixed on Dynavax hepatitis vaccine

Advisors to the US Food and Drug Administration have backed the efficacy of Dynavax' hepatitis B vaccine Heplisav but expressed concerns about its safety profile.

The agency's Vaccines and Related Biological Products Advisory Committee voted 13 to one that the data presented by Dynavax adequately demonstrated immunogenicity. However, they also voted eight to five with one abstention that there was insufficient data to adequately support the safety of Heplisav.

The vote was no great surprise, following documents released earlier in the week by FDA staff concerning trials which compared Heplisav with  GlaxoSmithKline's older vaccine Engerix B. The staffers had noted that while the incidence of autoimmune events in Heplisav-Engerix B studies were low, all of them occurred in the Heplisav arms.

The panel was also concerned about the lack of representation of Asian-Americans, African-Americans and Hispanics in the studies which involved nearly 5,850 patients. The committee suggested that the database of patients may need to be double that.

Dynavax said it will continue working with the FDA as it completes its review ahead of the scheduled Prescription Drug User Fee Act date for Heplisav of February 24. Investors fear the worse, however, and Dynavax shares sank over 60% in extended trading.

Click here to order a reprint of this news story.


Your Comments

Tell us what you think.

Twitter Go to @PharmaTimes

Find a job

Website Search

Search News Search Magazine

Business Insight


Competitions News


International Clinical Researcher of the Year 2016

Book your tickets today!


Most read articles

Latest Jobs